DABUR INDIA LTD. - 500096 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst/ Institutional Investor Meet11-02-2022
11-02-2022
DABUR INDIA LTD. - 500096 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Investors'' Conference Call for Dabur India Limited Q3 FY 2021-22 - Financial Results08-02-2022
Dabur India to launch party snacks and dry fruit under Real Health
Sources told CNBC-TV18 that the company is also set to launch millet-based foods under the sub-brand07-02-2022
Buy Dabur India; target of Rs 725: Sharekhan
Sharekhan is bullish on Dabur India has recommended buy rating on the stock with a target price of Rs 725 in its research report dated February 03, 2022.04-02-2022
DABUR INDIA LTD. - 500096 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the officials of the Company shall be attending, Edelweiss India Conference 2022 on 8th February, 2022, through Video Conference03-02-2022
DABUR INDIA LTD. - 500096 - Link For Audio Recording Of Investors' Conference Call For Dabur India Limited - Q3 FY 2021-22 Financial Results
Link for Audio recording of Investors' Conference Call for Dabur India Limited - Q3 FY 2021-22 Financial Results03-02-2022
DABUR INDIA LTD. - 500096 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Unaudited Financial Results for the Quarter and nine months ended on 31.12.202103-02-2022
Earnings Call for Q3FY22 of Dabur India
Conference Call with Dabur India Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.03-02-2022
Dabur Q3 Net Profit Rises 2.19% To Rs 504.35 Crore
Dabur India Limited on Wednesday reported a 2.19 per cent increase in consolidated net profit to Rs 504.35 crore for December quarter02-02-2022
Q3FY22 Quarterly Result Announced for Dabur India Ltd.
Personal Products company Dabur India declares Q3FY22 result: Dabur Q3 Consol. Revenue Up 8% at Rs 2,942 Crore Dabur India Ltd today reported an 8% growth in Consolidated Revenue for the Quarter ended December 31, 2021 on a very high base of the previous year, with the 9-month Consolidated Revenue reporting a 16% growth year-on-year. Dabur India Ltd braved the heavy inflationary pressures, a significant moderation in industry growth and dip in overall consumer sentiments to deliver a competitive and healthy Consolidated Revenue growth of 8% at Rs 2,942 Crore in the third quarter of 2021-22 financial year, up from Rs 2,729 Crore in the same quarter a year ago. Consolidated Revenue for the quarter reported a 2-year CAGR of 11.8%, reflecting the remarkable agility and resilience the business continues to demonstrate even in a tough market. Operating Profit for the quarter reported a strong 9.3% growth ahead of the Topline growth. Consolidated Net Profit for the third quarter was up 2.3% to cross the Rs 500 Crore mark for the second time in a row and ended at Rs 503 Crore, as against Rs 492 Crore a year ago. Consolidated Net Profit for the 9-month period marked a 10% growth, while the India FMCG Business reported a 13% Volume growth for the 9-month period. "The overall operating environment remained challenging throughout the quarter with unprecedented inflation of 13% and subdued consumer sentiments. We have mitigated the impact of inflation partially through calibrated price increases and cost-saving initiatives. Despite these macro-economic headwinds, we remained focused on rolling our consumer-centric innovation that expanded our total addressable market, besides gaining market share across 100% of our product portfolio, which is unprecedented. Our investments in distribution footprint expansion in rural India helped drive growth even in a challenging environment with rural demand for Dabur outpacing urban demand by 500bps," Dabur India Ltd Chief Executive Officer Mr. Mohit Malhotra said. "There has been a marked revival in discretionary spending by consumers, which helped the Home & Personal care business grow by 8.4%. While our Healthcare portfolio was impacted due to the high base of the previous year and a marked drop in demand for COVID-contextual products, this business reported a 2-year CAGR of 11.4%. Excluding the COVID-contextual range of Chyawanprash and Honey, our domestic FMCG Volume Growth stood at 8% for the third quarter," Mr. Mohit Malhotra said. Result PDF02-02-2022